av Kristofer | 22 maj, 2026 | Nyheter, LSI Zeta
Celebration! Happy to precent LSI Zeta second investment; Mesenkia Therapeutics AB✨ . Specializing in the development of next generation single domain antibodies. Mesenkia is a pre-clinical company developing the hashtag#next-generation biological drug candidates...
av Kristofer | 13 mars, 2026 | Nyheter, LSI Zeta
It is with great joy we can present LSI Zetas first investment CubaseBio. Drug discovery is still slow, expensive, and inefficient.While hashtag#organoids are becoming a powerful model system, researchers lack spatial tools that scale with these complex...
av Kristofer | 20 januari, 2026 | Nyheter
https://www.di.se/digital/anglarna-som-trotsar-trenden-nytt-miljonregn-till-life-science
av Kristofer | 20 januari, 2026 | Nyheter
Press Release – January 2026 Life Science Invest’s sixth co-investment company, LSI Zeta, has raised EUR 2,9 million from 35 Nordic business angels with broad expertise in life science. The company will invest in around ten early-stage life science companies in the...
av Kristofer | 27 oktober, 2025 | LSI Epsilon, Nyheter
We are happy to introduce LSI Epsilons 9th investment Abarceo Pharma AB, a pre-clinical stage company, developing a platform for the treatment of mitochondrial diseases, with an initial focus on Type 2 Diabetes (T2D).We look forward to work closely with Adam Bruce,...
